Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour

Neil Pugashetti; Stanley A Yap; Primo N Lara Jr; Regina Gandour-Edwards; Marc A Dall'Era

doi:10.5489/cuaj.2447

Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E204-7. doi: 10.5489/cuaj.2447.

Authors

Neil Pugashetti¹, Stanley A Yap¹, Primo N Lara Jr², Regina Gandour-Edwards³, Marc A Dall'Era¹

Affiliations

¹ Department of Urology, University of California, Davis, Sacramento, CA;
² Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis, Sacramento, CA;
³ Department of Pathology, University of California, Davis, Sacramento, CA.

Abstract

Primary signet-ring cell carcinoma (SRCC) of the urinary bladder, a variant of adenocarcinoma, is exceedingly rare and as a result no gold standard exists for its management. We report a case of primary SRCC of the bladder with recurrent metastases; we utilized an innovative diagnostic approach and the patient exhibited a treatment response to palliative FOLFOX-6 chemotherapy.